TG Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference

Core Insights - TG Therapeutics, Inc. will participate in the 8th Annual Evercore Healthcare Conference from December 2-4, 2025, with a fireside chat scheduled for December 2, 2025, at 12:30 PM ET [1] Company Overview - TG Therapeutics is a fully integrated, commercial-stage biopharmaceutical company focused on developing and commercializing novel treatments for B-cell diseases [3] - The company has received FDA approval for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease [3] - BRIUMVI has also received approval from several regulatory agencies outside the U.S. for treating adult patients with relapsing multiple sclerosis who have active disease defined by clinical or imaging features [3]